Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Pfizer says coronavirus vaccine study shows mostly mild to moderate side effects

Pfizer says coronavirus vaccine study shows mostly mild to moderate side effects



FILE PHOTO A man walks past a sign in front of Pfizer’s headquarters in the Manhattan neighborhood of New York, New York, USA, July 22, 2020. REUTERS / Carlo Allegri

(Reuters) – Pfizer Inc. PFE.N participants said Tuesday they showed mostly mild to moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing study at a late stage.

In a presentation to investors, the company said side effects include fatigue, headaches, chills and muscle aches. Some participants in the process also developed a fever ̵

1; including several high fevers. The data is blinded, which means that Pfizer does not know which patients received the vaccine or placebo.

Catherine Jansen, head of research and development at Pfizer’s vaccines, said the independent data monitoring committee “has access to non-blind data to let us know if they have any safety concerns and haven’t done so so far.”

The company has involved more than 29,000 people in 44,000 volunteer studies to test the experimental vaccine COVID-19, which it is developing with German partner BioNTech. 22UAy.F.

More than 12,000 study participants received a second dose of the vaccine, Pfizer executives said during a conference call for investors.

The comments follow AstraZeneca’s competition AZN.L The COVID-19 vaccine trials, which are being held worldwide on September 6, after a serious side effect was reported in a volunteer in the UK.

The lawsuits against AstraZeneca resumed in Britain and Brazil on Monday after a green light from British regulators, but are still pending in the United States.

Pfizer expects there will likely be results if the vaccine works in October.

“We believe – given the very strong immune profile, as well as the preclinical profile … that the effectiveness of the vaccine is likely to be 60% or more,” said Mikael Dolsten, Pfizer’s chief scientific officer.

Report by Manas Mishra in Bengaluru and Michael Herman from Maplewood, New Jersey; Edited by Arun Koyur, Shunak Dasgupta and Aurora Ellis


Source link